XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Convertible Preferred Stock
Series A
Convertible Preferred Stock
Series A Non-Voting
Convertible Preferred Stock
Series B Non-Voting
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Series A Non-Voting
Total
Balances at Feb. 05, 2024 $ 3 $ (2)   $ 1
Balances (in Shares) at Feb. 05, 2024 3,197,975        
Issuance of common stock $ 2 (2)  
Issuance of common stock (in Shares)       2,207,553        
Issuance of Series A convertible preferred stock, net of issuance costs of $69 $ 2,931  
Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) 20,000,000              
Stock-based compensation expense 17   17
Net loss (7,077)   (7,077)
Balances at Mar. 31, 2024 $ 2,931 $ 5 13 (7,077)   (7,059)
Balances (in Shares) at Mar. 31, 2024 20,000,000 5,405,528        
Balances at Feb. 05, 2024 $ 3 (2)   1
Balances (in Shares) at Feb. 05, 2024 3,197,975        
Net loss               (57,943)
Balances at Sep. 30, 2024 $ 52,841 $ 2,931 $ 35 397,345 (57,943)   342,368
Balances (in Shares) at Sep. 30, 2024 2,439 137,138 34,998,550     2,439  
Balances at Mar. 31, 2024 $ 2,931 $ 5 13 (7,077)   (7,059)
Balances (in Shares) at Mar. 31, 2024 20,000,000 5,405,528        
Stock-based compensation expense 321   321
Net loss (22,243)   (22,243)
Balances at Jun. 30, 2024 $ 2,931 $ 5 334 (29,320)   (28,981)
Balances (in Shares) at Jun. 30, 2024 20,000,000 5,405,528        
Stock-based compensation expense         1,750     1,750
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization $ (2,931) $ 2,931   2,931
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares) (20,000,000)   137,138          
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization $ 3 26,445   26,448
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) 2,722,207        
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, $ 20 248,437   248,457
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares) 20,061,932        
Issuance costs of Pre-Closing Financing and reverse recapitalization (20,480)   (20,480)
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization $ 1 4,999   5,000
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares) 1,208,883        
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing $ 56,097 $ 6 144,433   144,439
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares) 2,439 5,600,000        
Issuance cost of PIPE Financing   $ (3,256)     (8,573)     (8,573)
Net loss (28,623)   (28,623)
Balances at Sep. 30, 2024 $ 52,841 $ 2,931 $ 35 $ 397,345 $ (57,943)   $ 342,368
Balances (in Shares) at Sep. 30, 2024 2,439 137,138 34,998,550     2,439